All In Biotech

Drug Trial Radar · NCT06583031

Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years

A Phase 1, Randomized, Modified Double-blind, Multi-center, Parallel Group, Multi-arm Study to Investigate the Safety and Immunogenicity of an RSV/hMPV Vaccine Candidate in Adult Participants Aged 60 to 75 Years

Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 385 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

385

Actual

Start

Oct 9, 2024

Primary completion

Oct 9, 2025

Study completion Oct 9, 2025

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.

Conditions

  • RSV Infection
  • hMPV

Interventions

  • RSV/hMPV vaccine dose A1Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose A2Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose A3Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose B1Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose B2Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose B3Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose C1Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose C2Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose C3Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose 1Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose 2Biological

    Suspension for injection. Route of administration: IM injection

  • RSV/hMPV vaccine dose 3Biological

    Suspension for injection. Route of administration: IM injection

  • Monovalent RSV VaccineBiological

    Suspension for injection. Route of administration: IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of any unsolicited systemic Adverse Events (AEs) reported within 30 minutes after vaccinationTime frame: On Day 1
  2. Presence of solicited injection site and systemic reactions (ie, pre-listed in the participant's diary and in the eCRF (electronic case report form) occurring through 7 days after vaccinationTime frame: Day 1 through day 8
  3. Presence of unsolicited AEs reported through 28 days after vaccinationTime frame: Day 1 through day 29
  4. Presence of SAEs (Serious Adverse Events) and AESIs (Adverse Events of Special Interest) throughout the study (ie, through 6 months after vaccinationTime frame: SAE: Screening through day 181; AESI: Day 1 through day 181
  5. Presence of out-of-range biological test results (including shift from baseline values) through 7 days after vaccinationTime frame: Screening through day 8

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Site # 0361004

    Botany, New South Wales, Australia

  • Site # 031001

    Brookvale, New South Wales, Australia

  • Site # 0361006

    Miranda, New South Wales, Australia

  • Site # 0361002

    Wollongong, New South Wales, Australia

  • Site # 0361003

    Herston, Queensland, Australia

  • Site # 0361005

    South Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.